| [1] |
Polednak AP. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers [J]. Cancer Detect Prev,2008,32(3):190-199.
|
| [2] |
Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women [J]. J Natl Cancer Inst,2009,101(1):48-60.
|
| [3] |
Pan H,Gray RG. Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials[EB/OL]. [2014-06-20]. http:/ /meetinglibrary. asco. org/content/133648-144.
|
| [4] |
Piccart-Gebhart M, Holmes AP, Basega J, et al. First results from the phase III ALTTO trial(BIG 2-06;NCCTG[Alliance]N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence(T→L), or their combination(T+L) in the adjuvant treatment of HER2-positive early breast cancer(EBC)[EB/OL].[2014-06-20].http:/ /meetinglibrary.asco.org/content/128258-144.
|
| [5] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet,2012,379(9816):633-640.
|
| [6] |
Pagani O,Regan MM, Walley BA,et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer [J].N Engl J Med,2014,371(2):107-118.
|
| [7] |
Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer[J]. J Clin Oncol,2010,28(7):1145-1153.
|
| [8] |
Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol,2010,28(3):375-379.
|
| [9] |
von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial [J]. Lancet Oncol,2014,15(7):747-756.
|
| [10] |
Von Minckwitz G,Hahnen E,Fasching PA,et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA(gBRCA) mutation and triple-negative breast cancer(TNBC):Results from GeparSixto [EB/OL]. [2014-06-20]. http:/ /meetinglibrary.asco.org/content/131770-144.
|
| [11] |
Miller K, O'Neill AM, Dang CT, et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103 [EB/OL].[2014-06-20]. http:/ /meetinglibrary. asco. org/content/130506-144.
|
| [12] |
Slamon DJ, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer[J]. Cancer Res,2013,73(24 Suppl): S1-3.
|
| [13] |
Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumabcontaining therapy in triple-negative breast cancer(BEATRICE): primary results of a randomised, phase 3 trial[J]. Lancet Oncol,2013,14(10):933-942.
|
| [14] |
Tredan O, Follana P, Moillet I, et al. AROBASE: a phase III trial of exemestane ( Exe) and bevacizumab ( BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV—A GINECO study [EB/OL]. [2014-06-20]. http:/ /meetinglibrary.asco.org/content/131820-144.
|